Media

Five things for pharma marketers to know: Friday, April 17

Five things for pharma marketers to know: Friday, April 17

By

The FDA approves generic Copaxone; AstraZeneca's experimental lung-cancer drug demonstrates that it can delay disease progression; PhRMA CEO John Castellani to step down

Doximity to launch Apple Watch app

The app for the smartwatch includes secure encrypted messaging.

Print ads surface on programmatic exchanges

Time Inc., according to AdAge, has begun selling print ads for its magazines on exchanges.

MM&M's top reads of 2014

MM&M's top reads of 2014

A look at the content that grabbed most reader interest over the past year.

Haymarket launches psychiatry news, CME site

Haymarket Media launched the site PsychiatryAdvisor.com today.

Clinical researchers dip toe into social media

Clinical researchers dip toe into social media

By

Researchers are increasingly using social media to recruit patients, albeit oftentimes in an arms-length manner.

FDA Twitter guidance greeted with caution

FDA Twitter guidance greeted with caution

By

Guidance on promoting products in 140 characters and correcting misinformation serves as a guarded green light, says one observer.

Texting threatens pagers, work-life balance

Texting HCPs may be speedy, but a study finds some built-in risks.

Publicis, Facebook ink deal

The Omnicom-Publicis deal may have been scuttled, but the hunger for deals remains.

Ad chides Gilead "greed" over Sovaldi pricing

The AIDS Healthcare Foundation took out an ad in some WSJ editions saying the drug threatens to "break the bank."

AOL lands J&J marketing vet

AOL lands J&J marketing vet

By

Praised for helping navigate the shift by advertisers into digital, media vet Kim Kadlec is leaving pharma for a new role at AOL.

Adults increasingly using ADHD medications

Adults increasingly using ADHD medications

By

Express Scripts notes that these prescriptions may not, in fact, be for ADHD.

Off-label guidance may not be publishing boon

Off-label guidance may not be publishing boon

By

The FDA's proposed upgrade to its off-label distribution guidelines has some new features, but experts say it is unclear if this means more dollars will flow toward reprints.

New owner to publish MedAdNews biannually

New owner to publish MedAdNews biannually

By

A month after UBM Canon closed the B2B magazine, marketing firm Outcomes LLC announced its return to twice-a-year publication.

FTC wants media to be wary of ads

The agency says outlets need to rethink running ads that make false claims.

The year's most popular stories

The year's most popular stories

Our year-end list captures the 10 that sparked heaviest interest.

Nodding to bloggers, Lilly digitizes content

Nodding to bloggers, Lilly digitizes content

By

The move to digitize a series of books it co-created with Disney for kids with type 1 diabetes was spurred by a meeting with the online diabetes community.

Elsevier sends wave of takedown requests

Elsevier sends wave of takedown requests

By

Elsevier is taking a hard-line posture against several different universities, asking them to take down scholarly research.

Japan investigates cancer "articles"

The Heath, Labor and Welfare ministry says a publisher passed off advertorials as articles.

Pharma eyes EHR for engaging with docs

Pharma eyes EHR for engaging with docs

By

EHRs could be a vehicle for pharma to find its way into the physician's workflow. First, industry needs to learn how to leverage them appropriately.

AMA has closed the book on American Medical News

AMA has closed the book on American Medical News

By

American Medical News's 55-year publishing history ended September 2, although the website will be maintained through the end of the year.

Big Pharma pulls back on publishing

Big Pharma pulls back on publishing

By

A research team found that Big Pharma has pulled back on publications despite doubling or even quadrupling research and development budgets

Boehringer takes health and diabetes onto dance floor

Boehringer takes health and diabetes onto dance floor

By

The company has partnered with Univision on a dance competition that supports health and weight loss. The segment, called Ritmo Dieta, will run for 13 weeks on the variety program Sábado Gigante.

Blogs may smooth ups, downs of breast cancer: study

By

For women suffering from breast cancer, online tools appeared to be helpful in battling depression, a randomized trial showed.

Professional Media briefs: September 2013

Professional Media briefs: September 2013

By

News on JAMA Ophthalmology, the New England Journal of Medicine, Elsevier and Oxford University Press

Informed patients mean productive office visits: study

Informed patients mean productive office visits: study

By

A study published in JAMA Internal Medicine shows that encouraging patients to read up on a topic beforehand could make office visits more productive

MedPage Today broadens its scope

MedPage Today broadens its scope

By

MedPage Today's new VP and global editorial director, Ivan Oransky, has a goal in mind: to make the resource even more top-of-mind among the medical community by broadening and deepening its content and engagement

Remedy's HealthCentral.com is slated for a makeover

Remedy's HealthCentral.com is slated for a makeover

By

Remedy Health is hoping a new design for its flagship portal can give it an edge over rivals WebMD and Everyday Health.

AMA to shutter newspaper amid ad turmoil

AMA to shutter newspaper amid ad turmoil

By

American Medical News' 55-year publishing run will come to a close this year, the AMA, its publisher, said today.

WebMD caps search, chooses in-house CEO Schlanger

WebMD caps search, chooses in-house CEO Schlanger

By

David Schlanger is the company's new chief executive, a role he's filled on an interim basis since May.


A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.

Email Newsletters


Pharma continues to struggle with its image. Exhibit A is the public debate around the price of, and access to, new and innovative meds. As countless transformative technologies hit market, has industry done enough to anchor its permission to innovate? To provide a closer look at trends affecting trust over the past year, MM&M presents this e-book, "The 2015 Edelman Trust Barometer." Click here.